ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1327

Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment

Anna fishbein1, Rachel Lawson2, Veleka Allen1, Xiaozhong Zhang3, Laura Chambre4, Stephen Ruhmel1, Sophie Wilhelm1, Fredric Marrache5, Maria Wiekowski1, Markus Kohlmann6 and Jeffrey Curtis7, 1Sanofi, Morristown, NJ, 2Sanofi, Earley, United Kingdom, 3Sanofi, Chengdu, China (People's Republic), 4Sanofi, Cambridge, MA, 5Sanofi, Gentilly, France, 6Sanofi, Frankfurt, Germany, 7University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2025

Keywords: exercise, mood, physical activity, quality of life, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Patients with rheumatoid arthritis (RA) are less physically active than the general population, and these activity differences can be measured through digital devices. This systematic review examined various mechanisms by which mobility has been objectively measured in RA patients and highlighted findings on common digital endpoints related to mobility.

Methods: We performed a literature search using PubMed and Embase databases through August 2024 with search terms including mobility, physical activity, physical function, sedentary behavior, walking, and digital measurement technologies. After removing duplicates, 715 titles were screened, with 105 meeting inclusion criteria (Figure 1). Studies were categorized by primary aim: validation of digital technology, descriptive observational studies, assessment of interventions (e.g. initiation of RA treatment), and digital technology as a monitoring intervention itself. Technology used was assessed based on manuscript categorization.

Results: Among the 105 studies, 28 (26.7%) validated digital technology, 41 (39.0%) were descriptive observational studies, 30 (28.6%) assessed interventions, and 6 (5.7%) used digital technology as intervention. Accelerometers were the most commonly used digital device (n=54, 51.4%), followed by activity monitors (n=19, 18.1%), pedometers (n=6, 5.7%), and smartwatches (n=3, 2.9%). Commonly measured digital endpoints included daily step counts, sedentary time/behavior, and time spent in different physical activity intensities. RA patients showed greater sedentary behavior (9-10 h/day), and significantly less moderate-to-vigorous physical activity (p< 0.001) compared to matched controls (Belau MH, et al. 2024). Only 5-17% of RA patients met recommended physical activity guidelines (Bell K, et al. 2022, Khoja SS, et al. 2016). Patients with controlled disease showed greater physical activity than those with active disease (Barami T, et al. 2017). Physical activity was inversely related to fatigue (Rongen-van Dartel SA, et al. 2014) and positively associated with improved mood (Hegarty RSM, et al. 2015) and quality of life (Bell K, et al. 2022). Diurnal patterns revealed reduced activity in afternoons/evenings, with morning stiffness affecting early day mobility (Keogh A, et al. 2020, Prioreschi A, et al. 2013).

Conclusion: We identified numerous ways in which mobility is objectively measured in patients with RA by digital tools, with accelerometers as the predominant technology and step counts, sedentary time, and activity intensity as the key endpoints. Findings suggest that patients with RA are more sedentary and less active than healthy controls, with disease activity significantly influencing mobility patterns. Future work is planned to conduct a meta-analysis of findings described in this abstract.

Supporting image 1Figure 1: PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources


Disclosures: A. fishbein: Sanofi, 3; R. Lawson: Sanofi, 3; V. Allen: Sanofi, 3; X. Zhang: Sanofi, 3; L. Chambre: Sanofi, 3; S. Ruhmel: Sanofi, 3; S. Wilhelm: Sanofi, 3; F. Marrache: Sanofi, 3; M. Wiekowski: Sanofi, 3; M. Kohlmann: Sanofi, 3; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Bendcare, 5, Bristol-Myers Squibb(BMS), 5, Corrona, 2, 5, Crescendo, 2, 5, Eli Lilly, 2, 5, FASTER, 2, 4, Genentech, 2, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5, Moderna, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sanofi, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

fishbein A, Lawson R, Allen V, Zhang X, Chambre L, Ruhmel S, Wilhelm S, Marrache F, Wiekowski M, Kohlmann M, Curtis J. Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/systematic-review-of-mobility-in-rheumatoid-arthritis-with-digitally-measured-objective-assessment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systematic-review-of-mobility-in-rheumatoid-arthritis-with-digitally-measured-objective-assessment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology